ALPS Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-13,100
| Closed | -$236K | – | 1055 |
|
|
2025
Q1 | $236K | Sell |
13,100
-1,140
| -8% | -$20.5K | ﹤0.01% | 954 |
|
|
2024
Q4 | $240K | Buy |
+14,240
| New | +$240K | ﹤0.01% | 960 |
|
|
2022
Q4 | – | Sell |
-9,434
| Closed | -$111K | – | 1080 |
|
|
2022
Q3 | $111K | Sell |
9,434
-773
| -8% | -$9.1K | ﹤0.01% | 1027 |
|
|
2022
Q2 | $115K | Sell |
10,207
-7,438
| -42% | -$83.8K | ﹤0.01% | 1023 |
|
|
2022
Q1 | $528K | Sell |
17,645
-2,145
| -11% | -$64.2K | 0.01% | 423 |
|
|
2021
Q4 | $524K | Buy |
+19,790
| New | +$524K | 0.01% | 486 |
|
|
2020
Q4 | – | Sell |
-21,543
| Closed | -$517K | – | 874 |
|
|
2020
Q3 | $517K | Sell |
21,543
-1,453
| -6% | -$34.9K | 0.01% | 421 |
|
|
2020
Q2 | $421K | Sell |
22,996
-7,477
| -25% | -$137K | 0.01% | 471 |
|
|
2020
Q1 | $475K | Sell |
30,473
-3,553
| -10% | -$55.4K | 0.01% | 442 |
|
|
2019
Q4 | $728K | Buy |
34,026
+601
| +2% | +$12.9K | 0.01% | 450 |
|
|
2019
Q3 | $625K | Sell |
33,425
-1,570
| -4% | -$29.4K | ﹤0.01% | 449 |
|
|
2019
Q2 | $913K | Buy |
+34,995
| New | +$913K | 0.01% | 348 |
|
|
2016
Q2 | – | Sell |
-9,956
| Closed | -$207K | – | 634 |
|
|
2016
Q1 | $207K | Sell |
9,956
-1,706
| -15% | -$35.5K | ﹤0.01% | 602 |
|
|
2015
Q4 | $353K | Sell |
11,662
-2,191
| -16% | -$66.3K | ﹤0.01% | 628 |
|
|
2015
Q3 | $3.42K | Buy |
13,853
+5,104
| +58% | +$1.26K | ﹤0.01% | 641 |
|
|
2015
Q2 | $281K | Buy |
8,749
+4,382
| +100% | +$141K | ﹤0.01% | 660 |
|
|
2015
Q1 | $156K | Buy |
+4,367
| New | +$156K | ﹤0.01% | 646 |
|